COMMUNIQUÉS West-GlobeNewswire

Burcon’s Peazazz and Peazac Pea Proteins Receive Self-Affirmed GRAS Status
18/06/2018
GRAS Notification Submitted to US FDA VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (“Burcon” or the “Company”) a leader in natural product extraction, [...]
GPS SmartSole® Used to Predict Wandering of Individuals with Dementia
18/06/2018
George Mason University’s College of Health and Human Services Completes Phase II of Machine Learning Wandering Prediction Research LOS ANGELES, June 18, 2018 (GLOBE NEWSWIRE) -- GTX Corp (OTCBB:GTXO), an IoT platform [...]
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease
18/06/2018
First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer's Disease Research Unit and Yale PET Center Pittsburgh, June 18, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. , a clinical stage [...]
Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research
18/06/2018
Press Release 18 June 2018 Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research Immunicum AB (publ; IMMU.ST) announced today the online publication of a [...]
Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer
18/06/2018
Mr. Jafar Joins Evolus from Allergan as the Company Expands its Commercial Infrastructure IRVINE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to [...]
Tetra Bio-Pharma Takes on Fentanyl in Head to Head Trial for the Treatment of Breakthrough Pain
18/06/2018
First Clinical Study to Assess Cannabis as an Alternative to Fentanyl ORLEANS, Ontario, June 18, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., a leader in cannabinoid-based drug discovery and development (TSX VENTURE [...]
PolarityTE Provides Corporate Update on Company Progress
18/06/2018
SALT LAKE CITY, June 18, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, [...]
IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2018
18/06/2018
MONTRÉAL, June 18, 2018 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture:IBT) today reported its financial results for the nine months ended April 30, 2018. “We are pleased to see the [...]
Exalenz Announces Confidential Submission of Draft Registration Statement for Initial Public Offering
18/06/2018
MODI’IN, Israel and MANASQUAN, N.J., June 18, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of [...]
Allan R. Mendez, DPT, SCS is Selected to the American Health Council’s Physical Therapy Board
18/06/2018
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- The American Health Council selected Allan R. Mendez, DPT, SCS to its Board of Physical Therapy for his outstanding contributions to improving his patients’ health and well- [...]
Everett Jolly, Host of “Stock Day” Welcomes Richard T. Schumacher of Pressure BioSciences Back on the Show to Discuss Significant Debt to Equity Conversions and other Recent Accomplishments
18/06/2018
PHOENIX, June 18, 2018 (GLOBE NEWSWIRE) -- Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and “the Company”) was recently interviewed on Uptick Newswire’s “Stock Day” podcast [...]
Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions
18/06/2018
Columbia University to present data demonstrating CAEL-101 positively impacts myocardial function in patients with AL amyloidosis as measured by global longitudinal strain NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- [...]
TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA)
18/06/2018
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced an oral presentation of clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s PI3K [...]
Eloxx Appoints Global Pharmaceutical Leader, Neil Belloff, Executive Vice President, General Counsel and Corporate Secretary
18/06/2018
WALTHAM, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat [...]
Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
18/06/2018
BOSTON, June 18, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration (FDA) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T [...]
Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer
18/06/2018
SALT LAKE CITY, June 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has [...]
Helius Medical Technologies, Inc. Provides Update on its Anticipated Submission for FDA Clearance of the PoNS™ Device
18/06/2018
NEWTOWN, Pa., June 18, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, updated today the expected [...]
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis
18/06/2018
Partial suppression of estradiol with moderate dose (75mg) of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being High dose (200mg) of linzagolix achieves full estradiol [...]
Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
18/06/2018
-- Further Improvements Observed in Bardet-Biedl Syndrome Patients; Initial Proof-of-Concept Data in Alström Syndrome Demonstrates Significant Weight Loss and Decreased Hunger -- -- Rhythm Plans to Initiate Combined [...]

Pages